US5702359A
(en)
*
|
1995-06-06 |
1997-12-30 |
Genetronics, Inc. |
Needle electrodes for mediated delivery of drugs and genes
|
US5993434A
(en)
*
|
1993-04-01 |
1999-11-30 |
Genetronics, Inc. |
Method of treatment using electroporation mediated delivery of drugs and genes
|
US6261281B1
(en)
*
|
1997-04-03 |
2001-07-17 |
Electrofect As |
Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
|
CN1261808A
(zh)
*
|
1997-06-30 |
2000-08-02 |
罗纳-布朗克罗莱尔股份有限公司 |
向多细胞真核生物的细胞中转移核酸的改进方法和用于实施该方法的组合
|
JP2002507985A
(ja)
*
|
1997-06-30 |
2002-03-12 |
ローヌ−プーラン・ロレ・エス・アー |
横紋筋に核酸を導入する改良法およびその組合せ
|
US6241701B1
(en)
|
1997-08-01 |
2001-06-05 |
Genetronics, Inc. |
Apparatus for electroporation mediated delivery of drugs and genes
|
US6055453A
(en)
|
1997-08-01 |
2000-04-25 |
Genetronics, Inc. |
Apparatus for addressing needle array electrodes for electroporation therapy
|
US20040229363A1
(en)
*
|
1998-06-24 |
2004-11-18 |
Ed Nolan |
High efficiency transfection based on low electric field strength, long pulse length
|
US7922709B2
(en)
|
1998-07-13 |
2011-04-12 |
Genetronics, Inc. |
Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
|
US6678556B1
(en)
|
1998-07-13 |
2004-01-13 |
Genetronics, Inc. |
Electrical field therapy with reduced histopathological change in muscle
|
EP2428249B1
(de)
|
1998-07-13 |
2015-10-07 |
Inovio Pharmaceuticals, Inc. |
Haut- und muskelgerichtete Gentherapie mithilfe eines gepulsten elektrischen Felds
|
AU2868200A
(en)
*
|
1999-02-08 |
2000-08-25 |
Chiron Corporation |
Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
|
US6593130B1
(en)
*
|
1999-04-16 |
2003-07-15 |
The Regents Of The University Of California |
Method and apparatus for ex vivo and in vivo cellular electroporation of gene protein or drug therapy
|
CA2401239A1
(en)
*
|
2000-03-03 |
2001-09-13 |
Valentis, Inc. |
Improved poloxamer and poloxamine compositions for nucleic acid delivery
|
AU2001264759B2
(en)
|
2000-05-22 |
2006-06-01 |
Merck & Co., Inc. |
System and method for assessing the performance of a pharmaceutical agent delivery system
|
US6733485B1
(en)
|
2001-05-25 |
2004-05-11 |
Advanced Bionics Corporation |
Microstimulator-based electrochemotherapy methods and systems
|
US20040204669A1
(en)
*
|
2001-07-05 |
2004-10-14 |
Hofmann Gunter A. |
Apparatus for electroporation mediated delivery for drugs and genes
|
US7713740B2
(en)
*
|
2001-08-24 |
2010-05-11 |
University Of South Florida |
Method of using electric fields to facilitate the entry of molecules into cells in vivo
|
DK1436397T3
(da)
|
2001-10-11 |
2010-08-09 |
Merck Sharp & Dohme |
Hepatitis C virus vaccine
|
ES2344253T3
(es)
|
2001-10-11 |
2010-08-23 |
MERCK SHARP & DOHME CORP. |
Vacuna contra el virus de la hepatitis c.
|
IL161862A0
(en)
*
|
2001-11-08 |
2005-11-20 |
Univ California |
Methods and compositions for correction of cardiac conduction disturbances
|
EP1474153A4
(de)
*
|
2001-12-14 |
2005-12-14 |
Genetronics Inc |
Verfahren zur partikelunterstützten polynukleotidimmunisierung mit einem gepulsten elektrischen feld
|
EP1470161A1
(de)
*
|
2002-01-18 |
2004-10-27 |
Inovio AS |
Bispezifische antikörper-dna-konstrukte für die intramuskuläre verabreichung
|
US20050154434A1
(en)
|
2002-03-07 |
2005-07-14 |
Adam Simon |
Clinical syringe with electrical stimulation aspects
|
US7245963B2
(en)
*
|
2002-03-07 |
2007-07-17 |
Advisys, Inc. |
Electrode assembly for constant-current electroporation and use
|
US8209006B2
(en)
|
2002-03-07 |
2012-06-26 |
Vgx Pharmaceuticals, Inc. |
Constant current electroporation device and methods of use
|
US6912417B1
(en)
|
2002-04-05 |
2005-06-28 |
Ichor Medical Systmes, Inc. |
Method and apparatus for delivery of therapeutic agents
|
JP4499427B2
(ja)
|
2002-04-16 |
2010-07-07 |
サイト パルス サイエンシズ、インコーポレイテッド |
電場の移動及び電極極性の反転で生体材料を処理する方法。
|
US20040106896A1
(en)
*
|
2002-11-29 |
2004-06-03 |
The Regents Of The University Of California |
System and method for forming a non-ablative cardiac conduction block
|
US7328064B2
(en)
|
2002-07-04 |
2008-02-05 |
Inovio As |
Electroporation device and injection apparatus
|
JP5221127B2
(ja)
|
2004-03-08 |
2013-06-26 |
アイコアー メディカル システムズ、インク. |
電気を利用した治療剤移送のための改良された装置
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
EP1865969A4
(de)
*
|
2005-03-19 |
2009-07-15 |
Univ California |
Ultraschwach elektrofeldnetz-vermittelte ex vivo gen-, protein- und arzneiabgabe in zellen
|
CA2610919C
(en)
|
2005-06-17 |
2013-09-10 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Hepatitis c virus nucleic acid vaccine
|
EP1984007B1
(de)
*
|
2006-02-13 |
2015-08-19 |
Oncolytics Biotech Inc. |
Verwendung von niedrigdosiertem lokaler immunsuppression zur verstärkung einer onkolytischen viralen therapie
|
KR20090080941A
(ko)
|
2006-11-17 |
2009-07-27 |
제네트로닉스, 인코포레이티드 |
전기천공법을 이용한 백신접종 및 부스팅을 사용하여 면역 반응을 강화시키는 방법들
|
KR101383476B1
(ko)
|
2007-11-01 |
2014-04-11 |
아스테라스 세이야쿠 가부시키가이샤 |
면역억제 폴리펩티드 및 핵산
|
CN107083391A
(zh)
*
|
2008-04-04 |
2017-08-22 |
宾夕法尼亚大学托管会 |
屈曲病毒蛋白共有序列、编码该屈曲病毒蛋白共有序列的核酸分子和组合物及其使用方法
|
JP5873717B2
(ja)
|
2008-04-04 |
2016-03-01 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Il−28及び組成物を用いたワクチン及び免疫治療薬並びにその使用方法
|
EP2147697A1
(de)
|
2008-07-21 |
2010-01-27 |
Centre National De La Recherche Scientifique-CNRS |
Verfahren und Vorrichtung zur Anwendung elektrischer Felder in leitfähiges Material
|
EP2156860A1
(de)
|
2008-08-20 |
2010-02-24 |
Centre National De La Recherche Scientifique-CNRS |
Verfahren zur Herstellung isolierter Elektroden zum Einfügen elektrischer Felder in ein leitfähiges Material
|
US20100298697A1
(en)
*
|
2009-05-19 |
2010-11-25 |
Medtronic, Inc. |
Method and devices for improved efficiency of rna delivery to cells
|
US8207138B2
(en)
|
2009-05-19 |
2012-06-26 |
Medtronic, Inc. |
Methods and devices for improved efficiency of RNA delivery to cells
|
US8624011B2
(en)
|
2009-09-14 |
2014-01-07 |
The Trustees Of The University Of Pennsylvania |
Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
|
CA3177356A1
(en)
|
2009-11-02 |
2011-05-05 |
The Trustees Of The University Of Pennsylvania |
Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
|
US8298820B2
(en)
|
2010-01-26 |
2012-10-30 |
The Trustees Of The University Of Pennsylvania |
Influenza nucleic acid molecules and vaccines made therefrom
|
EP2539354B1
(de)
|
2010-02-08 |
2017-04-05 |
The Trustees Of The University Of Pennsylvania |
Für rantes kodierende nukleinsäuremoleküle sowie zusammensetzungen und verfahren damit
|
CA2812789A1
(en)
|
2010-09-27 |
2012-04-12 |
The Trustees Of The University Of Pennsylvania |
Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria
|
BR112013011705B1
(pt)
|
2010-11-12 |
2022-04-05 |
The Trustees Of The University Of Pennsylvania |
Antígenos de próstata de consenso, molécula de ácido nucleico quecodifica os mesmos e vacina e usos compreendendo os mesmos
|
EA033467B1
(ru)
|
2011-01-31 |
2019-10-31 |
Univ Pennsylvania |
Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение
|
US9238679B2
(en)
|
2011-02-11 |
2016-01-19 |
The Trustees Of The University Of Pennslyvania |
Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
|
HUE049669T2
(hu)
|
2011-02-11 |
2020-10-28 |
Univ Pennsylvania |
Hepatitis B vírus magfehérjéjét kódoló nukleinsav-molekula és azt tartalmazó oltóanyag
|
CA2839196A1
(en)
|
2011-06-15 |
2012-12-20 |
Chrontech Pharma Ab |
Injection needle and device
|
ES2758713T3
(es)
|
2011-07-11 |
2020-05-06 |
Inovio Pharmaceuticals Inc |
Vacuna de ADN contra el virus de Lassa
|
EP2791362B1
(de)
|
2011-12-12 |
2019-07-03 |
The Trustees Of The University Of Pennsylvania |
Proteine mit mrsa pbp2a und fragmenten davon, nucleinsäuren zur codierung davon sowie zubereitungen und deren verwendung zur vorbeugung und behandlung von mrsa-infektionen
|
KR20220132652A
(ko)
|
2011-12-12 |
2022-09-30 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
|
WO2013155205A1
(en)
|
2012-04-10 |
2013-10-17 |
The Trustees Of The University Of Pennsylvania |
Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same
|
EP4190350A1
(de)
|
2012-04-12 |
2023-06-07 |
The Trustees Of The University Of Pennsylvania |
Filovirus-konsensusantigene, nukleinsäurekonstrukte und daraus hergestellte impfstoffe sowie verfahren zur verwendung davon
|
DE102012013534B3
(de)
|
2012-07-05 |
2013-09-19 |
Tobias Sokolowski |
Vorrichtung für repetitive Nervenstimulation zum Abbau von Fettgewebe mittels induktiver Magnetfelder
|
WO2014064534A2
(en)
|
2012-10-05 |
2014-05-01 |
Chrontech Pharma Ab |
Injection needle, device, immunogenic compositions and method of use
|
KR102258021B1
(ko)
|
2012-12-13 |
2021-06-01 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Wt1 백신
|
US11419925B2
(en)
|
2013-03-15 |
2022-08-23 |
The Trustees Of The University Of Pennsylvania |
Cancer vaccines and methods of treatment using the same
|
CA2895806C
(en)
|
2013-03-15 |
2023-02-21 |
The Trustees Of The University Of Pennsylvania |
Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
|
US10272144B2
(en)
|
2013-07-31 |
2019-04-30 |
Bioventures, Llc |
Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens
|
CN105829341A
(zh)
|
2013-12-13 |
2016-08-03 |
宾夕法尼亚大学理事会 |
Dna抗体构建体及其使用方法
|
CN114010802A
(zh)
|
2014-12-01 |
2022-02-08 |
宾夕法尼亚大学理事会 |
Dna抗体构建体及其使用方法
|
US11491342B2
(en)
|
2015-07-01 |
2022-11-08 |
Btl Medical Solutions A.S. |
Magnetic stimulation methods and devices for therapeutic treatments
|
US11266850B2
(en)
|
2015-07-01 |
2022-03-08 |
Btl Healthcare Technologies A.S. |
High power time varying magnetic field therapy
|
US20180001107A1
(en)
|
2016-07-01 |
2018-01-04 |
Btl Holdings Limited |
Aesthetic method of biological structure treatment by magnetic field
|
US10695575B1
(en)
|
2016-05-10 |
2020-06-30 |
Btl Medical Technologies S.R.O. |
Aesthetic method of biological structure treatment by magnetic field
|
WO2017055522A1
(en)
|
2015-09-29 |
2017-04-06 |
Academisch Medisch Centrum |
Stabilized env proteins of hiv
|
US11253717B2
(en)
|
2015-10-29 |
2022-02-22 |
Btl Healthcare Technologies A.S. |
Aesthetic method of biological structure treatment by magnetic field
|
JP7123800B2
(ja)
|
2016-02-05 |
2022-08-23 |
イノビオ ファーマシューティカルズ,インコーポレイティド |
がんのワクチン及びそれを用いた処置の方法
|
EA038691B1
(ru)
|
2016-03-28 |
2021-10-05 |
Айкор Медикэл Системс, Инк. |
Устройство для доставки терапевтических средств
|
WO2017180770A1
(en)
|
2016-04-13 |
2017-10-19 |
Synthetic Genomics, Inc. |
Recombinant arterivirus replicon systems and uses thereof
|
US11247039B2
(en)
|
2016-05-03 |
2022-02-15 |
Btl Healthcare Technologies A.S. |
Device including RF source of energy and vacuum system
|
US11464993B2
(en)
|
2016-05-03 |
2022-10-11 |
Btl Healthcare Technologies A.S. |
Device including RF source of energy and vacuum system
|
US11534619B2
(en)
|
2016-05-10 |
2022-12-27 |
Btl Medical Solutions A.S. |
Aesthetic method of biological structure treatment by magnetic field
|
US10583287B2
(en)
|
2016-05-23 |
2020-03-10 |
Btl Medical Technologies S.R.O. |
Systems and methods for tissue treatment
|
US10556122B1
(en)
|
2016-07-01 |
2020-02-11 |
Btl Medical Technologies S.R.O. |
Aesthetic method of biological structure treatment by magnetic field
|
CA3040264A1
(en)
|
2016-10-17 |
2018-04-26 |
Synthetic Genomics, Inc. |
Recombinant virus replicon systems and uses thereof
|
CN110352247A
(zh)
|
2016-12-05 |
2019-10-18 |
杨森制药公司 |
用于增强基因表达的组合物和方法
|
WO2019042950A1
(en)
|
2017-08-26 |
2019-03-07 |
Academisch Medisch Centrum |
IMPROVED HIV ENVELOPE GLYCOPROTETIC IMMUNOGENS
|
US11235044B2
(en)
|
2017-12-13 |
2022-02-01 |
Inovio Pharmaceuticals, Inc. |
Cancer vaccines targeting MUC16 and uses thereof
|
CA3083528C
(en)
|
2017-12-13 |
2023-09-12 |
Inovio Pharmaceuticals, Inc. |
Cancer vaccines targeting mesothelin and uses thereof
|
BR112020011443A2
(pt)
|
2017-12-13 |
2020-12-01 |
Inovio Pharmaceuticals, Inc. |
molécula de ácido nucleico e seu uso, vetor e seu uso, composição, proteína e vacina
|
US11021692B2
(en)
|
2017-12-19 |
2021-06-01 |
Janssen Sciences Ireland Unlimited Company |
Hepatitis B virus (HBV) vaccines and uses thereof
|
EA202091516A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
|
EP4272833A3
(de)
|
2017-12-19 |
2024-01-10 |
Janssen Sciences Ireland Unlimited Company |
Hepatitis b virus (hbv) impfstoff und verwendung
|
US11389531B2
(en)
|
2017-12-19 |
2022-07-19 |
Janssen Sciences Ireland Unlimited Company |
Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
|
WO2019123250A1
(en)
|
2017-12-19 |
2019-06-27 |
Janssen Sciences Ireland Unlimited Company |
Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
|
CN111902163B
(zh)
|
2018-01-19 |
2024-02-13 |
杨森制药公司 |
使用重组复制子系统诱导和增强免疫应答
|
EP3721939B1
(de)
|
2019-04-11 |
2022-07-06 |
BTL Healthcare Technologies a.s. |
Vorrichtung zur ästhetischen behandlung biologischer strukturen durch hochfrequenz und magnetische energie
|
WO2020255019A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and a quinazoline derivative
|
CN114340663A
(zh)
|
2019-06-18 |
2022-04-12 |
爱尔兰詹森科学公司 |
乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合
|
EP3986915A1
(de)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Konstrukt aus rekombinantem interleukin 12 und verwendungen davon
|
WO2020255018A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Hepatitis b virus (hbv) vaccines and uses thereof
|
US20220305116A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences lreland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
|
WO2020255035A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyrimidine derivatives
|
WO2020255017A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
|
US20220241402A1
(en)
|
2019-06-18 |
2022-08-04 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
|
WO2020255013A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives
|
TW202114731A
(zh)
|
2019-06-18 |
2021-04-16 |
愛爾蘭商健生科學愛爾蘭無限公司 |
B型肝炎病毒(HBV)疫苗與靶向HBV之RNAi之組合
|
US20220296703A1
(en)
|
2019-06-18 |
2022-09-22 |
Janssen Sciences Ireland Unlimited Company |
Cobmination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
US20220249647A1
(en)
|
2019-06-18 |
2022-08-11 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
|
US20220233684A1
(en)
|
2019-06-18 |
2022-07-28 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors
|
WO2020255010A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
|
WO2020255038A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
WO2020255022A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
|
CA3143634A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
|
CA3140588A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor
|
WO2020254876A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Virus-like particle delivery of hepatitis b virus (hbv) vaccines
|
WO2020255042A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and a pyrimidine derivative
|
WO2020255016A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
|
AU2020297019A1
(en)
|
2019-06-20 |
2022-02-17 |
Janssen Sciences Ireland Unlimited Company |
Carbohydrate nanocarrier delivery of hepatitis B virus (HBV) vaccines
|
EP3986563A1
(de)
|
2019-06-20 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Lipidnanopartikel oder liposomenabgabe von hepatitis-b-virus-(hbv)-impfstoffen
|
US11878167B2
(en)
|
2020-05-04 |
2024-01-23 |
Btl Healthcare Technologies A.S. |
Device and method for unattended treatment of a patient
|
KR20230000081U
(ko)
|
2020-05-04 |
2023-01-10 |
비티엘 헬쓰케어 테크놀로지스 에이.에스. |
환자의 무인 치료를 위한 디바이스 및 방법
|
CN116133668A
(zh)
|
2020-06-12 |
2023-05-16 |
罗切斯特大学 |
ACE-tRNA的编码和表达
|
KR20230050328A
(ko)
|
2020-07-08 |
2023-04-14 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
Hbv에 대한 rna 레플리콘 백신
|
WO2022133230A1
(en)
|
2020-12-18 |
2022-06-23 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
WO2022146654A1
(en)
|
2020-12-28 |
2022-07-07 |
Janssen Pharmaceuticals, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
US11896816B2
(en)
|
2021-11-03 |
2024-02-13 |
Btl Healthcare Technologies A.S. |
Device and method for unattended treatment of a patient
|
WO2023150753A1
(en)
|
2022-02-07 |
2023-08-10 |
University Of Rochester |
Optimized sequences for enhanced trna expression or/and nonsense mutation suppression
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|